nach oben

Clinical and Translational Oncology

Erschienen in:

01.12.2013 | Clinical Guides in Oncology

SEOM clinical guidelines for the treatment of head and neck cancer (HNC) 2013

verfasst von: R. Mesía, M. Pastor, J. J. Grau, E. del Barco

Erschienen in: Clinical and Translational Oncology | Ausgabe 12/2013

Einloggen, um Zugang zu erhalten

Abstract

Head and neck cancer represents 5 % of oncologic cases in adults. Early stage treatments are local with surgery and/or radiotherapy. For locally advanced stages, treatment requires radiotherapy combined with platinum-based drugs or cetuximab. Induction chemotherapy should be considered for selected cases. In the case of metastatic disease, adjuvant or palliative treatment is based on platinum agents and cetuximab.

Nur mit Berechtigung zugänglich

Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H et al. Cancer incidence and mortality in Europe: estimates for 40 countries in 2012. Eur J Cancer (online version). 2013. doi:10.1016/j.ejca.2012.12.027.

TNM Classification. American Joint Committee on Cancer: AJCC Cancer Staging Manual. 7th ed. New York: Springer; 2010.

Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck cancer. N Engl J Med. 2001;345(26):1890–900.PubMedCrossRef

Winquist E, Oliver T, Gilvert R. Postoperative chemoradiotherapy for advanced squamous cell carcinoma of the head and neck: a systematic review with meta-analysis. Head Neck. 2007;29:38–46.PubMedCrossRef

Pignon JP, Bourhis J, Domenge C, Designé L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer. Lancet. 2000;355:949–55.PubMed

Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354(6):567–78.PubMedCrossRef

Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11:21–8.PubMedCrossRef

Vermorken JB, Remenar E, Van Herpen C, Gorlia T, Mesía R, Degardin M, et al. Cisplatin, fluorouracil and docetaxel in unresectable head and neck cancer. Phase III trial EORTC 24971/TAX 323. NEJM. 2007;357:1695–704.PubMedCrossRef

Posner MR, Hershock DM, Blajman CR, Michiewicz E, Winquist E, Gorbounova V, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. TAX 324 Study Group. NEJM. 2007;357:1705–25.PubMedCrossRef

10.

Lefebvre JL, And KK. Larynx preservation clinical trial design: key issues and recommendations. A consensus panel summary. Int J Radiation Oncol Biol Phys. 2009;73:1293–303.

11.

VA Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Departament of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med. 1991;324:1685–90.

12.

Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003;349:2091–8.PubMedCrossRef

13.

Forastiere AA, Zhang Q, Weber RS, Maor MH, Goepfert H, Pajak TF, et al. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol. 2013;31:845–52.PubMedCrossRef

14.

Pointreau Y, Garuad P, Chapet S, Sire C, Tuchais C, Tortochaux J, et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer. 2009;101:498–506.

15.

Bonner JA, Harari M, Giralt J, Baselga J, Shin D, Cohen R et al. Improved preservation of larynx with the addition of cetuximab to radiotherapy for cancers of the larynx and hypopharynx. J Clin Oncol. 2005;23(16S):5533.

16.

Lefebvre JL, Pointreau Y, Rolland F, Alfonsi M, Baudoux A, Sire C, et al. Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study. J Clin Oncol. 2013;31(7):853–9.PubMedCrossRef

17.

Hitt R, López-Pousa A, Martínez-Trufero J, Escrig V, Carles J, Rizo A, et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol. 2005;23:8636–45.PubMedCrossRef

18.

Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359(11):1116–27.

19.

Hitt R, Irigoyen A, Cortes Funes H, Grau JJ, García-Sáenz JA, Cruz-Hernandez JJ et al. Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Ann Oncol. 2012;23:1016–22.

Titel: SEOM clinical guidelines for the treatment of head and neck cancer (HNC) 2013
verfasst von: R. Mesía
M. Pastor
J. J. Grau
E. del Barco
Publikationsdatum: 01.12.2013
Verlag: Springer Milan
Erschienen in: Clinical and Translational Oncology / Ausgabe 12/2013
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-013-1096-z

Neu im Fachgebiet Onkologie

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

SEOM clinical guidelines for the treatment of head and neck cancer (HNC) 2013

Abstract

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2013

SEOM clinical guidelines for the management of metastatic breast cancer 2013

SEOM clinical guidelines for the treatment of small-cell lung cancer 2013

SEOM clinical guidelines for the adjuvant treatment of colorectal cancer 2013

SEOM guide to antiemetic prophylaxis in cancer patients treated with chemotherapy 2013

SEOM clinical guidelines for the treatment of nasopharyngeal carcinoma 2013

SEOM Clinical Guidelines for the systemic treatment of early breast cancer 2013

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie